Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC-DAD

BACKGROUND: Ombitasvir/paritaprevir/ritonavir/dasabuvir (Viekira Pak(®)) are the newest medicines approved for use in the treatment of hepatitis C virus (HCV) and are available in tablet form as an oral combination. Specifically, these agents are indicated in the treatment of HCV in patients with ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Zoman, Nourah Zoman, Maher, Hadir Mohamed, Al-Subaie, Amal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214962/
https://www.ncbi.nlm.nih.gov/pubmed/28101128
http://dx.doi.org/10.1186/s13065-016-0232-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214962/
https://www.ncbi.nlm.nih.gov/pubmed/28101128
http://dx.doi.org/10.1186/s13065-016-0232-6

Ejemplares similares